Apontis Pharma AG (ETR:APPH)
Germany · Delayed Price · Currency is EUR 10.85
+0.05 (0.46%)
Aug 1, 2025, 5:36 PM CET
Apontis Pharma AG Company Description
Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes.
The company was founded in 1946 and is based in Monheim am Rhein, Germany. As of November 21, 2024, Apontis Pharma AG operates as a subsidiary of Zentiva AG.
Apontis Pharma AG
| Country | Germany |
| Founded | 1946 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 137 |
| CEO | Bruno Wohlschlegel |
Contact Details
Address: Alfred-Nobel-Str. 10 Monheim am Rhein, 40789 Germany | |
| Phone | 49 2173 8955 4949 |
| Website | apontis-pharma.de |
Stock Details
| Ticker Symbol | APPH |
| Exchange | Deutsche Börse Xetra |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | DE000A3CMGM5 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bruno Eugen Wohlschlegel | Chief Executive Officer and Chairman of Management Board |
| Thomas Milz | Chief Product Officer and Deputy Chairman of Management Board |
| Thomas Zimmermann | Chief Financial Officer and Member of Management Board |